CPF as a free ligand exists in 6 entries. Examples include: 5BTC 4BVV 1OYE

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Identifiers1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid
FormulaC17 H18 F N3 O3
Molecular Weight331.34
Isomeric SMILESOC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O

Chemical Details

Formal Charge0
Atom Count42
Chiral Atom Count0
Chiral Atomsn/a
Bond Count45
Aromatic Bond Count6
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00537 Different stereochemistry
  • approved
  • investigational
DescriptionA broad-spectrum antimicrobial carboxyfluoroquinoline. [PubChem]
  • 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
  • 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
  • 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
  • 1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid
  • 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
SaltsCiprofloxacin Hydrochloride
Brand Names
  • Act Ciprofloxacin
  • Apo-ciproflox
  • Auro-ciprofloxacin
  • Bio-ciprofloxacin
  • Ciloxan
Affected OrganismEnteric bacteria and other eubacteria
IndicationFor the treatment of the following infections caused by susceptible organisms: urinary tract infections, acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea, and inhalational anthrax (post-exposure).
PharmacologyCiprofloxacin is a broad-spectrum antiinfective agent of the fluoroquinolone class. Ciprofloxacin has <i>in vitro</i> activity against a wide range of gram-negative and gram-positive microorganisms. The mechanism of action of quinolones, including ciprofloxacin, is different from that of other antimicrobial agents such as beta-lactams, macrolides, tetracyclines, or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin. There is no known cross-resistance between ciprofloxacin and other classes of antimicrobials. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.
Mechanism of actionThe bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.
Route of administration
  • Auricular (otic)
  • Intratympanic
  • Intravenous
  • Ophthalmic
  • Ophthalmic; Topical
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antibacterials for Systemic Use
  • Antiinfectives for Systemic Use
  • Antineoplastic Agents
  • J01MA02
  • J01RA11
  • J01RA12
  • S02AA15
  • S03AA07
  • 08:12.18
  • 52:04.04
CAS number85721-33-1
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682